PDL1/aAPC/Raji
CBP74145
詢 價
索取Protocol
產品描述
產品數(shù)據庫
| I. Background | |
| Programmed Cell Death Protein 1 (PD-1),一種在激活的 T 細胞上表達的受體，與其配體 PD-L1 和 PD-L2 結合，負向調節(jié)免疫反應。 PD-1 配體存在于大多數(shù)癌癥中，PD-1:PD-L1/2 相互作用會抑制 T 細胞活性，并使癌細胞逃避免疫監(jiān)視。 PD1/PDL1信號轉導通路是腫瘤免疫抑制的重要組成部分，可以抑制T淋巴細胞的興奮，增強腫瘤細胞的免疫耐受，從而實現(xiàn)腫瘤免疫逃逸。 | |
| II. Introduction | |
| Expressed gene: | PD-L1、aAPC |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of Anti-PD-L1 Blocking Antibody in PD-1-IL2 Pathway Effector Reporter Cells (C37) With Raji PD-L1 aAPC Cells.
Figure 2. Dose Response of Anti-PD-1 Blocking Antibody in PD-1-IL2 Pathway Effector Reporter Cells (C37) With Raji PD-L1 aAPC Cells.
